AXL has a prognostic role in metastatic colorectal cancer (mCRC) and is a predictive biomarker of lack of efficacy of chemotherapy (CT) + cetuximab in RAS wild type (WT) patients (pts)

Authors :: Davide Ciardiello
D. Rizzi
Fortunato Ciardiello
P. Vitale
Nicola Normanno
Paola Vitiello
N. Zanaletti
C. Borrelli
Mariel C. Paul
Erika Martinelli
Anna Maria Rachiglio
Tiziana Latiano
Giulia Martini
B. Blauensteiner
L. Poliero
Veronica Moreno-Viedma
Maria Sibilia
Vincenzo Famiglietti
Claudia Cardone
Evaristo Maiello
Source :: Annals of Oncology. 29:viii30
Publication Year :: 2018
Publisher :: Elsevier BV, 2018.

Full Text Access

Tools